Non-linear dosing of mirdametinib
US11806321B2 · kind B2 · utility
8Cited by
3References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2023 |
| Grant date | Nov 7, 2023 |
| Priority date | — |
| Expiry date | Mar 16, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to methods for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by administering to a patient in need thereof mirdametinib or a pharmaceutically acceptable salt thereof, such as by a certain dosing scheme.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.